AstraZeneca Plc - AZN Earnings per share for the last 12 months

Public company logo of AstraZeneca Plc (AZN)

High accountability for scientific breakthroughs creates reputational challenges for AstraZeneca PLC (AZN). The current YoY EPS shift over the last 12 months demonstrates a support zone where the value of 17.60 expresses the metric level. Exclusive oncology patents and inelastic demand for therapy, along with the pricing power to recover medical investments, ensure stability.

AZN AstraZeneca Plc: Earnings per share for the last twelve months in the range 02/11/2024 - 11/14/2026

AstraZeneca AB - analytical breakdowns and key metrics (AZN)

- share price and expert price forecast:
Price Chart astrazeneca.com|AZN - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization AstraZeneca Plc|AZN - Enterprise Value
- book capitalization indicators:
Net Assets per Share AstraZeneca|AZN - Company Book Value|Capitalization to Book Value Ratio astrazeneca.com|AZN - Company Total Assets
- company total debt and liquidity indicators:
Debt to Capital Ratio AstraZeneca PLC|AZN - Long-Term Debt to Capital|Short-Term Debt to Capital AstraZeneca Corp.|AZN - Company Debts|Debts to Net Assets AstraZeneca Plc|AZN - Company Long-Term Liabilities|Amount of Current Liabilities AstraZeneca|Intermediate Coverage Ratio astrazeneca.com
- business earnings and investment ratios data:
AZN - Net Profit|Projected Future Earnings AstraZeneca PLC|AZN - Price to Earnings Ratio|Price to Expected Earnings Ratio AstraZeneca Plc|AZN - PEG Multiple|Company Value to EBITDA AstraZeneca Plc|AZN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months AstraZeneca|AZN - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months astrazeneca.com|AZN - Earnings growth in current year|Expected earnings per share growth for next year AstraZeneca PLC
- revenue and sales details:
AZN - Revenue and Sales Volume|Projected Sales Volume astrazeneca.com|AZN - Market Cap to Revenue|Forward Price to Sales AstraZeneca Plc
Initial company analysis:AZN (astrazeneca.com)
Signature product of AstraZeneca AB

This indicator measures the relative change in earnings per share over the last twelve months, allowing for an assessment of real capital generation efficiency. The trend of this metric serves as a leading signal for investors to revise the asset's fair value. By analyzing the net income per share YoY ttm growth rate chart, one can identify deviations of actual income from projected values. For AstraZeneca PLC (AZN), such efficiency directly depends on the implementation of robotic screening and logistics automation, which reduce development costs.

Direct competitors

LLY: Earnings per share for the last twelve months|ABBV: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NVS|MRK (Merck Sharp & Dohme) - Net earnings per share (EPS TTM)|Novo Nordisk Group (NVO) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Amgen Inc. (AMGN)|pfizer.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) SNY (Sanofi S.A.)|Net earnings per share for the trailing year Bristol Myers Squibb Company|GSK Corp - Net earnings per share (EPS TTM)|TAK - Net earnings per share (EPS TTM)|tevapharm.com (TEVA) - Earnings per share for the last twelve months|RDY - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months VTRS|ROIV (Roivant) - Earnings per share for the last four quarters|Earnings per share for the last twelve months Zai Lab Ltd. (ZLAB)|BHC (Bausch Health Corp) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) COSM (Cosmos Health Inc.)